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Abstract  
 
Transfected human ASK1 produces a 150kDa protein. However, we have detected 
endogenous ASK1 predominantly as 39kDa and 50kDa C-terminal and 75kDa and 
110kDa N-terminal fragments in a panel of non-transfected cancer cell lines and HUVEC 
endothelial cells. This suggests that in non-apoptotic cells, endogenous ASK1 protein is 
normally cleaved at a number of specific sites, some of which are in the kinase domain. 
Transfected ASK1 protein is known to be degraded by the proteasome. In contrast, the 
cleavage of endogenous ASK1 is independent of the proteasome as treatment with the 
proteasome inhibitor, lactacystin did not inhibit cleavage. Cisplatin treatment decreased 
the amount of 39kDa C-terminal ASK1 fragment in mutant p53 cell lines suggesting a 
decrease in cleavage associated with apoptosis. Transfected ASK1 may therefore not 
accurately reflect the role of endogenous ASK1. 
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Introduction 
 
ASK1 (Apoptosis Signal-Regulating Kinase 1) is a member of the mitogen activated 
protein (MAP) kinase family of proteins and is involved in the regulation of apoptosis. 
ASK1 is endogenously expressed at low levels so the vast majority of experimental work 
characterising ASK1 has been performed in transfected cell lines. The human ASK1 
protein consists of 1375 amino acids with a serine/threonine kinase domain in the middle 
of the molecule (1). The N and C-terminals of ASK1 are coiled-coil domains (1) to which 
regulatory molecules such as thioredoxin and glutaredoxin bind respectively to inhibit 
ASK1 kinase activity (2). ASK1 has been shown to be regulated by ubiquitination, 
inactive ASK1 with bound thioredoxin is a target for degradation by the proteasome (3). 
 
The majority of studies of ASK1’s regulation and interaction with the apoptotic pathways 
has been performed in cell lines transfected with the pcDNA3-ASK1-HA plasmid (4). 
While these studies are useful in elucidating the function of ASK1 and its role in the 
apoptotic pathways, such artificially high levels of ASK1 may produce different results to 
endogenous levels of ASK1. We have examined the endogenous expression of ASK1 in a 
panel of non-transfected cell lines and have found that ASK1 is cleaved into two major 
fragments which may represent a novel mechanism of inactivation in non-apoptotic cells. 
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Methods 
 
Cell Culture 
 
The human cancer cell lines H69, CEM, U87-MG were obtained from the ATCC 
(Virginia, USA). HUVEC cells were obtained by primary culture. H69 and CEM cells 
were grown in antibiotic-free RPMI (Thermoelectron, Sydney, Australia) with 10% 
Foetal Calf Serum (FCS) (Thermoelectron). U87-MG cells were grown in antibiotic-free 
D-MEM/F-12 (Gibco via Invitrogen, Melbourne, Australia) with 20% FCS. HUVEC 
cells were grown in D-MEM/F-12 with 20% FCS, 50µg/ml heparin, 50µg/ml endothelial 
cell growth supplement and 40µg/ml gentamycin. All cells were maintained in a 
humidified atmosphere with 5% CO2 at 37°C. Cultures were mycoplasma free. The 
suspension cell lines (H69 and CEM) were treated with cisplatin, MG132, lactacystin or 
leupeptin at a cell density of 5.0 x 10
5
/ml. The attached cell lines (U87-MG and HUVEC) 
were seeded for drug treatment such that the control flasks would reach confluence after 
48 hours.  
 
Transfection of ASK1 into H69 cells 
 
The pcDNA3-ASK1-HA plasmid was a gift from Dr. Hidenori Ichijo (4). Plasmids were 
purified from JM109 cells using a Qiagen (Melbourne, Australia) Endofree Plasmid Maxi 
Kit. 1.3 x 10
6
 H69 cells were resuspended in 1.6ml RPMI with serum and 0.1mg/ml 
neomycin in a 6 well plate. 0.8µg plasmid DNA in 100µl Qiagen Buffer EC was 
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combined with 6.4µl Qiagen Enhancer and 40µl Qiagen Effectene transfection reagent 
and incubated for 10 minutes at room temperature. 600µl RPMI was added and the 
transfection mix added to the cells. 
 
Western Blotting 
 
Cells were washed in cold PBS (0.15M NaCl, 0.03M NaH2PO4, 0.07M Na2HPO4 , pH 
7.2), and resuspended in 100µl of lysis buffer (0.01M Tris/HCl, pH 7.4) at 4°C. 10µl 
complete protease inhibitor (Roche, Sydney, Australia) was added prior to sonnication. 
20µg protein was then electrophoresed and Western blotted as previously described (5), 
with the following modifications. A 12% acrylamide Tris/glycine gels with a 4% stacking 
gel was used and Biorad markers or Biorad broad range markers were used as indicated 
(Biorad, Sydney, Australia). Primary antibodies used were anti-ASK1 C-terminal epitope 
1275-1290 (Upstate, Melbourne, Australia). Anti-ASK1 C-terminal epitope 1076-1375 
(Santa Cruz Biotechnology via Monarch Medical, Brisbane, Australia). Anti-ASK1 N-
terminal epitope 20 amino acids surrounding 280 (Cell Signaling Technology, via 
Genesearch, Brisbane, Australia). The ASK1 antibodies were used at a dilution of 1:500, 
1:200 and 1:500 respectively. The anti ASK1 C-terminal inhibition peptide, the epitope 
of the antibody (EEKDQEIKHLKLKSQP-NH2), was incubated with the primary 
antibody at a ratio of 5:1 (Upstate). The p21
WAF1  
antibody (Clone CP74 from Labvision), 
was used at a 1:1000 dilution. The secondary antibody used was an alkaline phosphatase 
conjugated rabbit immunoglobin (Chemicon, Melbourne, Australia), diluted 1:500. 
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Results 
 
Endogenous ASK1 is cleaved 
 
ASK1 was examined by Western blot using a C-terminal ASK1 antibody in H69, CEM, 
and U87-MG cancer cell lines and in HUVEC endothelial cells (Figure 1A). This 
revealed a prominent 39kDa band in all cell lines, a 50kDa band and some multi-banding 
in the 150kDa range, the size of full-length ASK1, in the U87-MG and HUVEC cells. A 
low molecular weight fragment of ASK1 has not been previously reported in the 
literature so we investigated the specificity of the antibody. The major 39kDa and 50kDa 
bands as well as the higher molecular weight minor bands were absent on incubation with 
an inhibition peptide, the epitope of the antibody (Figure 1B). A blast search of human 
protein sequences also confirmed that the C-terminal antibody’s epitope was specific to 
human ASK1 (6). Another C-terminal ASK1 antibody (Santa Cruz Biotechnology) was 
tested on the H69 cells and the same 39kDa band was detected (data not shown), 
suggesting that the 39kDa band was not an artefact of individual antibody. 
 
An N-terminal ASK1 antibody detected 2 prominent bands both smaller than 150kDa 
(Figure 1C). The molecular weights of the C and N-terminal fragments were calculated 
and averaged from at least 5 independent Western blots using 2 different molecular 
weight markers for quantitation (Figure 1D). When the size of the major and minor bands 
were added from both the C and N-terminal, the total approaches the molecular weight of 
full-length ASK1. Figure 1E suggests potential cleavage sites determined by the size of 
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the fragments using the data from Figure 1D using the protein size calculator Protcalc (7). 
This suggests that there are several cleavage sites which may cleave and inactivate the 
kinase domain or alter the normal regulation of kinase activity. The C-terminal of the 
protein is cleaved away into the 39kDa fragment and the kinase domain may also be 
cleaved forming the 50kDa fragment.  
 
As a control the pcDNA3-ASK1-HA plasmid (4) was transfected into H69 cells to test if 
full-length ASK1 could be detected using the C-terminal ASK1 (upstate) antibody 
(Figure 1F). The 39kDa band is present in all samples, the 150kDa band is present in the 
ASK1 transfected sample 72 hours after transfection and not in any of the transfection 
controls. This indicates that the C-terminal ASK1 antibody is capable of detecting full-
length ASK1 when it is overexpressed. 
 
Modulation of ASK1 cleavage products in response to cisplatin 
 
Cells were treated with 5µg/ml cisplatin for 48 hours, a dose high enough to trigger cell 
cycle arrest and apoptosis. The amount of the 39kDa C-terminal ASK1 band decreased in 
response to cisplatin treatment in the H69 and CEM cells which have mutant p53 (Figure 
2A). Some faint bands were also observed in the ~150kDa region in response to cisplatin 
treatment suggesting that some full-length ASK1 may be present in the apoptotic 
samples. Earlier and later time points were also examined, however, no clear 150kDa 
ASK1 band was detected. There was no change in amount of the 39 or 50kDa bands in 
wild type p53 cells U87-MG and HUVEC. 
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Is the proteasome responsible for ASK1 cleavage? 
 
ASK1 is inactivated by ubiquitination and degradation in cell lines which have been 
transfected with ASK1 (3). As the 39kDa band was so sharp we theorised that it was the 
product of a specific cleavage rather than degradation by the proteasome. H69 cells were 
treated with 10µM MG132 a reversible proteasome inhibitor for 24 and 48 hours. As a 
positive control for proteasome inhibition the accumulation of cell cycle protein p21 was 
examined (Figure 3A). The 48-hour MG132 treatment caused an accumulation of p21 
suggesting successful proteasome inhibition and the C-terminal ASK1 fragment 
disappeared. This suggested that the proteasome may be involved in the degradation of 
endogenous ASK1. However, MG132 is also known to inhibit certain lysosomal cysteine 
proteases and calpains and have apoptotic activity (8). Therefore another proteasome 
inhibitor lactacystin was used to confirm the involvement of the proteasome. Leupeptin 
which inhibits the calpains, trypsin and cathepsins (9) was also used to examine the role 
of these proteases. H69 cells were treated with 10µM lactacystin or 8µg/ml leupeptin for 
48 hours (Figure 3B). No reversal of ASK1 cleavage was observed suggesting that the 
proteasome, calpains, trypsin and cathepsins are not involved in ASK1 cleavage. 
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Discussion  
 
Why have these ASK1 fragments not been previously reported? 
 
Although full-length 150kDa ASK1 was easily detected in ASK1-transfected cells by an 
antibody to the C-terminal of ASK1, it was not detected in the non-transfected cells. 
Instead, all cells had a prominent sharp band at 39kDa suggesting that endogenous ASK1 
may be specifically cleaved. These bands occurred in a panel of cancer cell lines H69, 
CEM and U87-MG as well as in HUVEC endothelial cells suggesting that this is not just 
a cancer specific phenomenon. There are no reports of such cleavage of transfected 
ASK1. This may be because the majority of studies which have transfected ASK1 into 
cells using the pcDNA3-ASK1-HA plasmid have also used an HA antibody as a 
detection system rather than an ASK1 antibody, therefore not detecting any endogenous 
ASK1. Most publications also only show a narrow profile of the full-length ASK1 
150kDa region and not the entire length of the lane were cleavage products could be 
observed. The cleavage products of endogenous ASK1 may have been previously ignored 
as when ASK1 is transfected into cells, the 150kDa product becomes so intense that 
lower molecular weight bands may have been attributed to non-specific reactions.  
 
A role for cleaved endogenous ASK1 
 
Inactivation by ubiquitination and degradation has been well documented for transfected 
ASK1 (3), this process would not produce cleavage products to detect.  It is possible that 
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ubiquitination and degradation is not as important in the regulation of endogenous ASK1 
and that other mechanisms of degradation such as inactivation by cleavage can regulate 
the lower levels of ASK1 normally expressed. These large fragments of ASK1 may have 
a biological function as studies of transfection of truncated ASK1 have shown that 
thioredoxin and glutaredoxin still bind to the N and C-terminals and that that some 
truncated ASK1 proteins actually have increased kinase activity due to the loss of 
regulatory domains (10,11).  
 
There is a different pattern of ASK1 fragments which correlates with the p53 status of the 
cell line (Figure 2). The p53 mutant cell lines H69 and CEM have the 39kDa C-terminal 
band, whereas the p53 wild type cells U87-MG, HUVEC have both the 39kDa and 
50kDa C-terminal bands. The response of the cleavage products to cisplatin treatment is 
also different between p53 mutant and wild type cells. The wild type cells show no 
change in the amount of either bands. In contrast, the p53 mutant cells show a decrease in 
the 39kDa band, suggesting a decrease in ASK1 cleavage resulting in an increase in full-
length ASK1 in the apoptotic cells.  
 
Endogenous ASK1 is not cleaved by the proteasome 
 
The proteasome is not responsible for ASK1 cleavage as lactacystin did not reverse the 
cleavage. The proteasome is also unlikely to be involved as its function is to degrade 
proteins into small peptides of 3-20 residues not produce large protein fragments which 
could be biologically active (8). ASK1 is either cleaved by a protease which is inhibited 
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by MG132 (Figure 3) or MG132 is having an apoptotic effect and reversing the cleavage 
in a similar manner to the treatment with cisplatin (Figure 2). 
 
Conclusions 
 
Endogenous ASK1 is normally cleaved in cells, this cleavage is specific and may 
inactivate the kinase domain of the protein. The degradation of endogenous ASK1 is 
independent of the proteasome which is different to the degradation characterised for 
transfected ASK1. Transfected ASK1 may therefore not accurately model endogenous 
ASK1. 
 
Acknowledgements 
 
The authors would like to thank Prof. Hidenori Ichijo for providing the pcDNA3-ASK1-
HA plasmid. Dr. Sheridan Henness and Dr. Nigha Le for their advice on microbiology 
and transfection. Mrs Rozelle Harvie for performing the primary culture of  HUVEC 
cells.  
 12 
References 
 
 1.  Hayakawa,T. et al (2006) The ASK1-MAP kinase pathways in immune and stress 
responses. Microbes and Infection 8, 1098-1107. 
 2.  Song,J.J. et al (2003) Differential role of glutaredoxin and thioredoxin in metabolic 
oxidative stress-induced activation of apoptosis signal-regulating kinase 1 
Biochemical.Journal 373, 845-853. 
 3.  Liu,Y. et al (2002) Thioredoxin promotes ASK1 ubiquitination and degradation to 
inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circulation 
Research 90, 1259-1266. 
 4.  Ichijo,H. et al (1997) Induction of apoptosis by ASK1, a mammalian MAPKKK 
that activates SAPK/JNK and p38 signaling pathways Science 275, 90-94. 
 5.  Henness,S. et al (2002) Fractionated irradiation of H69 small-cell lung cancer cells 
causes stable radiation and drug resistance with increased MRP1, MRP2, and 
topoisomerase IIalpha expression International Journal of Radiation Oncology, Biology, 
Physics. 54, 895-902. 
 6.  Altschul,S.F. et al (1997) Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs.  Nucleic Acids Research 25, 3389-3402. 
 7.  Gill,S.C. et al (1989) Calculation of protein extinction coefficients from amino acid 
sequence data Analytical Biochemistry 182, 319-326. 
 8.  Lee,D.H. et al (1998) Proteasome inhibitors: valuable new tools for cell biologists. 
Trends in Cell Biology 8, 397-403. 
 9.  Zollner,H. (1989) Handbook of Enzyme Inhibitors. 
 10.  Saitoh,M. et al (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis 
signal-regulating kinase (ASK) 1 EMBO Journal 17, 2596-2606. 
 11.  Song,J.J. et al (2002) Role of glutaredoxin in metabolic oxidative stress. 
Glutaredoxin as a sensor of oxidative stress mediated by H2O2 Journal of Biological 
Chemistry 277, 46566-46575. 
 
Figure 1 – Analysis of ASK1 cleavage products. Protein from H69, U87-MG, HUVEC and 
CEM cells was analysed by Western blot with A) ASK1 C-terminal Antibody, B) ASK1 C-
terminal Antibody with inhibition peptide and C) ASK1 N-terminal Antibody. D) Molecular 
weights of ASK1 cleavage products. E) Potential cleavage sites of the ASK1 protein based on 
the molecular weights of cleavage products. F) Positive control transfection of ASK1. H69 cells 
were transfected with the pcDNA3-ASK1-HA plasmid and the C-terminal of ASK1 was 
analysed by Western Blot. Cells were analysed 24 and 72 hours post transfection.
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Figure 2 – Modulation of ASK1 cleavage products by cisplatin. 
A) H69, U87-MG, HUVEC and CEM cells were treated ± 5µg/ml 
cisplatin for 48 hours, and the C-terminal fragments of ASK1 analysed by 
Western Blot. The p53 status of each cell line is indicated. 
Figure 3 – Inhibition of ASK1 degradation with specific inhibitors.
H69 cells were treated A) ± 10µM MG132 and B) ± 10µM lactacystin or 
8µg/ml leupeptin for 48 hours. The C-terminal fragments of ASK1 and 
p21 were analysed by Western blot.
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